Parp inhibitors as monotherapy in daily practice for advanced prostate cancers

HIGHLIGHTS

• who: Diego Teyssonneau and colleagues from the Department of Medical Oncology, Institut Bergonié, Bordeaux, FranceDepartment of Urology, Hôpital Européen Georges-Pompidou, AP-HP, Paris University, Paris, France have published the research: PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers, in the Journal: (JOURNAL) of 07/03/2022
• what: Treatment with PARPis significantly improves overall survival for mCRPC patients.
• how: This review proposes a brief review of the rationale and outcomes of PARPi treatment then a pragmatic vision of PARPi use in terms of prescription and the selection of . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.